United Therapeutics (UTHR) | Stock Overview & Key Data
United Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $432.56
High: $444.57
on October 2, 2025
52 Week Range
Low: $266.98
High: $444.57
on April 9, 2025
on October 2, 2025
All-Time High: $444.57 on October 2, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$19.3B
EPS
25.12
P/E Ratio (TTM)
16.92
Forward P/E
15.25
P/B Ratio
2.68
PEG Ratio
1.77
Div. Yield
N/A
ROE
19.30%
Beta
0.619
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
89.03%
Operating Margin
45.64%
Profit Margin
40.36%
Returns and Earnings
Return on Assets (TTM)
12.96%
Return on Equity (TTM)
19.30%
EBITDA
$1.8B
Net Income (TTM)
$1.2B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$68.65
Quarterly Revenue Growth (YoY)
11.70%
Quarterly Earnings Growth (YoY)
11.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 82.52% | 56.54% | 92.68% | 104.13% | 700.67% |
| Neurocrine NBIX | 13.75B Large-cap | -2.95% | -3.65% | 5.67% | 26.25% | -0.81% | 19.95% | 26.32% | 30.95% |
| Viatris VTRS | 11.77B Large-cap | 6.53% | -4.26% | 8.24% | 16.74% | -18.60% | -12.77% | 15.68% | -35.36% |
| Zoetis ZTS | 63.73B | -1.63% | -7.29% | -7.89% | -11.87% | -11.75% | -26.34% | -3.23% | -12.26% |
Ownership & Short Interest
Insider Ownership
1.77%
Institutional Ownership
99.50%
Shares Short
3M
Short Ratio
3.12
Short % of Shares Outstanding
8.08%
Average 10-Day Volume
924K
Average 90-Day Volume
904K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is UTHR's 52-week high and low?
- In the last 52 weeks, United Therapeutics reached a high of $444.57 (on October 2, 2025) and a low of $266.98 (on April 9, 2025).
- What is the market cap and P/E ratio for UTHR?
- Curious about United Therapeutics's size and valuation? Its market capitalization stands at 19.33B. When it comes to valuation, the P/E ratio (trailing twelve months) is 16.92, and the forward P/E (looking ahead) is 15.25.
- Does UTHR pay dividends? If so, what's the yield?
- As for dividends, United Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are United Therapeutics's main competitors or similar companies to consider before investing?
When looking at United Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% Neurocrine
NBIX13.75B Healthcare Drug Manufacturers - Specialty & Generic 19.95% 26.32% Viatris
VTRS11.77B Healthcare Drug Manufacturers - Specialty & Generic -12.77% 15.68% Zoetis
ZTS63.73B Healthcare Drug Manufacturers - Specialty & Generic -26.34% -3.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for United Therapeutics Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of United Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.30%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 89.03%.
- What is the recent revenue and earnings growth for UTHR?
- Looking at United Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.70%, and quarterly earnings saw a YoY growth of 11.30%.
- How much of UTHR stock is held by insiders and institutions?
- Wondering who owns United Therapeutics stock? Company insiders (like executives and directors) hold about 1.77% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.